

February 07, 2022

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Scrip Symbol; THYROCARE

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
Script Code: 539871

Dear Sir/Madam,

Sub: Appointment of Managing Director & Chief Executive Officer – Intimation under Regulation 30 read with Part A to Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

--o--

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the Schedule III of the said Regulations, this is to inform you that the Board of Directors of the Company, at their meeting held on Saturday, 05th February, 2022, have approved appointment of Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. He will be joining by May 2022.

As MD & CEO, he will be a Key Managerial Personnel of the Company.

Brief Profile

A graduate of IIM-B, Rahul Guha joins API Group to head its Diagnostics Business. Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice.

Prior to joining BCG, Mr. Rahul Guha has been the co-founder and CEO of Nautilus Software and the Chief Technology Officer (CTO) at ValuePay.com where he was responsible for product development in the US Market. He has extensive project experience in MedTech and HealthTech and has worked closely with multiple startups on their digital incubation. He has been an active contributor to the Pharma sector and has over 2 decades of experience

We enclose a copy of press release which is being issued in this regard. This is for your information and records please.

Yours Faithfully,
For **Thyrocare Technologies Limited**,



Ramjee Dorai
Company Secretary and Compliance Officer



Thyrocare Technologies Limited



Thyrocare[®]
The Trust. The Truth.

Rahul Guha to join Thyrocare Technologies Limited as MD & CEO

Mumbai, 7th February, 2022: API Group backed Thyrocare Technologies Limited, a pan-India diagnostic laboratory services provider, has announced the appointment of Rahul Guha as the company's Managing Director and Chief Executive Officer w.e.f May 2022.

A graduate of IIM-B, Rahul Guha joins API Group to head its Diagnostics Business. Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice.

On the appointment - Siddharth Shah, MD and CEO at API Holdings had to say, "As we strive towards making healthcare affordable and accessible to every single Indian, we are extremely excited to have Rahul join us in our mission. I am elated to share that Rahul will be leading Thyrocare as its MD and CEO and will also be responsible for diagnostics as a segment at the group level. His invaluable experience of over two decades in healthcare will help us scale our diagnostics franchise."

Prior to joining BCG, Rahul has been the co-founder and CEO of Nautilus Software and the Chief Technology Office (CTO) at ValuePay.com where he was responsible for product development in the US Market. He has extensive project experience in MedTech and HealthTech and has worked closely with multiple startups on their digital incubation. He has been an active contributor to the pharma sector and has over 2 decades of experience.

On this announcement, Rahul Guha had to say, "I am very excited to join the phenomenal team at API Group and look forward to delivering a transformative customer experience to diagnostic users which will not only leverage the digital capabilities but also conjoin the extensive network of Thyrocare."

About Thyrocare

Thyrocare operates diagnostic centres focusing on providing diagnostic healthcare tests and allied services at affordable costs, through its network across India

About API Group

API Group is India's largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021) according to the RedSeer Report which operates an integrated, end-to-end business solving the healthcare needs of consumers through technology and fulfilment capabilities.

Disclaimer

"API Holdings Limited, part of API Group, is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus ("DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, Citigroup Global Markets India Private Limited and JM Financial Limited at www.investmentbank.kotak.com, www.morganstanley.com, www.ml-india.com, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm, and www.jmfl.com respectively, and the websites of the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP,ds when available. Potential investors should not rely on the DRHP for any investment decision."

For more information, please contact

Athira V Sunil, Concept PR - athira.v@conceptpr.in, +91 99872 89750

Shahab Shaikh, Concept PR - shahab@conceptpr.com, +91 +91 93208 97525

Chaitale Mehendale, API Holdings - chaitali.mehendale@pharmeasy.in, +91 77381 73206